FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average b	ourden							
- 1	hours ner resnonse.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GOWEN MAXINE				2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]								k all applica	•							
	,	irst) ERAPEUTICS, I	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/02/2022								Officer (below)	give title		Other (s below)	pecify			
(Street) WAYNE (City)	Pz	A tate)	19087 (Zip)	Dorio		4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transa Date				rative Securities Acquired, Disposed of, or Benefic action 2A. Deemed) or	5. Amount of 6. Ownership 7. Nature of				7. Nature of ndirect						
					Day/Y	Day/Year) if any (Month/Day)			Code (Instr. 5)					Beneficia Owned Fo Reported	ollowing (D) (I)		or Indirect nstr. 4)	Beneficial Ownership (Instr. 4)		
Common Stock 06/				06/0	3/202	2/2022		Code	V	Amount 3,356	(D)		Price	(Instr. 3 a	Transaction(s) (Instr. 3 and 4)		D			
Common Stock 06/03/2022																				
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction SA. Deemed Execution Date Execution Date, or Exercise (Month/Day/Year) if any		ate, Ti	5. Number of Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		mount	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				С	ode	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	or No of	umber		Transaction(s (Instr. 4)				
Stock Option (Right to Buy)	\$14.48	06/02/2022			A		15,750		(2)(3)		06/01/2032	Commo Stock	n 1:	5,750	\$0.00	15,75	0	D		
Restricted Stock Units	(1)	06/02/2022			A		4,507		(2)(4)		(2)(4) (4)		(4) Common Stock 4,		.,507	\$0.00	4,507		D	
Restricted Stock Units	(1)	06/03/2022			М			3,356	(5)		(5)	Commo Stock	n 3	,356	\$0.00	0		D		

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 2. This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy.
- 3. The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date.
- 4. The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date.
- 5. The shares underlying these restricted stock units vested on June 3, 2022.

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact

06/06/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.